Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
Open Access
- 1 June 2017
- journal article
- review article
- Published by Informa UK Limited in Cancer Management and Research
- Vol. ume 9, 207-213
- https://doi.org/10.2147/cmar.s136818
Abstract
Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis Sarah Chuzi,1 Fabio Tavora,2 Marcelo Cruz,3 Ricardo Costa,3 Young Kwang Chae,3 Benedito A Carneiro,3 Francis J Giles3 1Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 2Argos Laboratory, Messejana Heart and Lung Hospital, Fortaleza, Brazil; 3Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA Immune checkpoint inhibitors, including cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) inhibitors, represent an effective treatment modality for multiple malignancies. Despite the exciting clinical benefits, checkpoint inhibition is associated with a series of immune-related adverse events (irAEs), many of which can be life-threatening and result in significant treatment delays. Pneumonitis is an adverse event of special interest as it led to treatment-related deaths in early clinical trials. This review summarizes the incidence of pneumonitis during treatment with the different checkpoint inhibitors and discusses the prognostic significance of tumor type. The wide range of clinical, radiographic, and histologic characteristics of checkpoint inhibitor-related pneumonitis is reviewed and followed by guidance on the different management strategies. Keywords: immune checkpoint inhibitors, pneumonitis, anti-PD-1, anti-CTLA-4, immune-related adverse eventKeywords
This publication has 49 references indexed in Scilit:
- Pulmonary sarcoid-like granulomatosis induced by nivolumabBritish Journal of Dermatology, 2016
- PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical CourseClinical Cancer Research, 2016
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced CancerJAMA Oncology, 2016
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumabCancer, 2013
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyThe Lancet Oncology, 2010
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non–Small-Cell Lung Cancer Patients Treated With GefitinibJournal of Clinical Oncology, 2006
- Sirolimus‐associated interstitial pneumonitis in solid organ transplant recipientsClinical Transplantation, 2005